Back to top
more

BioDelivery Sciences International, Inc. (BDSI)

(Delayed Data from NSDQ)

$4.84 USD

4.84
695,323

+0.08 (1.68%)

Updated May 3, 2019 04:00 PM ET

After-Market: $4.85 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Endo (ENDP) Earnings & Revenues Beat in Q3, Generics Weak

Endo (ENDP) announced better-than-expected results for the third quarter. However, weakness in the generics segment persist and will impact results.

    BioDelivery (BDSI) Q3 Earnings, Sales Beat Estimates

    BioDelivery (BDSI) reports narrower-than-expected loss in Q3. Revenues also surpass estimates and increase significantly year over year.

      BioDelivery (BDSI) to Report Q3 Earnings: What's in Store?

      BioDelivery Sciences (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact third-quarter results remains to be seen.

        BioDelivery (BDSI) CEO Mark Sirgo to Retire by 2017 End

        BioDelivery Sciences (BDSI) President and CEO, Mark Sirgo, is set to retire this year.

          BioDelivery (BDSI) Q2 Loss Wider than Expected, Stock Falls

          BioDelivery Sciences International (BDSI) reported wider-than-expected Q2 loss. However, Belbuca registered record sales for the second consecutive quarter.

            What's in Store for BioDelivery (BDSI) This Earnings Season?

            BioDelivery Sciences International (BDSI) has been focusing on growth territories and expanding Bunavail's label. However, the extent to which these impact second-quarter results remains to be seen.

              BioDelivery-Purdue Pharma Ink Marketing Deal for Pain Drug

              BioDelivery Sciences International, Inc. (BDSI) announced an exclusive partnership agreement with Purdue Pharma, a Canadian pharmaceutical company, for commercializing its pain drug Belbuca in Canada.

                BioDelivery Inks New Contract with CVS/Caremark, Shares Up

                BioDelivery Sciences International, Inc. (BDSI) announced an agreement with CVS/Caremark to extend access to its pain management product Belbuca and opioid dependence product Bunavail through 2020.

                  BioDelivery Sciences (BDSI) Up 16.7% Since Earnings Report: Can It Continue?

                  BioDelivery Sciences (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                    BioDelivery Sciences International (BDSI) Jumps: Stock Up 5%

                    BioDelivery Sciences International, Inc. (BDSI) shares rose over 5% in the last trading session.

                      BioDelivery (BDSI) Q1 Earnings Beat Estimates, Stock Gains

                      BioDelivery Sciences International, Inc. (BDSI) reported earnings of 58 cents per share in the first quarter of 2017, which comfortably beat the Zacks Consensus Estimate of 9 cents.

                        What's in Store for BioDelivery (BDSI) this Earnings Season?

                        BioDelivery Sciences International, Inc. (BDSI) is expected to report first-quarter 2017 results later this month. Last quarter, the company???s loss was wider than expected.

                          BioDelivery (BDSI) Down 15% Since Earnings Report: Can It Rebound?

                          BioDelivery (BDSI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

                            BioDelivery to Grant New Patents for its Marketed Drugs

                            BioDelivery Sciences (BDSI) recently announced its decision to grant two new patents to extend the patent life for all three of its marketed products, Belbuca , Bunavail, and Onsolis.

                              BioDelivery (BDSI) Q4 Loss Wider Than Expected; Sales Meet

                              BioDelivery Sciences International, Inc. (BDSI) reported loss of 29 cents per share in the fourth quarter of 2016, slightly wider than the Zacks Consensus Estimate of a loss of 28 cents.

                                BioDelivery Q4 Loss Wider Than Expected; Revenues in Line

                                BioDelivery???s fourth-quarter 2016 loss of 29 cents per share is slightly wider than consensus estimates of 28 cents per share.

                                  BioDelivery (BDSI): What's in Store this Earnings Season?

                                  BioDelivery Sciences International, Inc. (BDSI) is expected to report fourth-quarter 2016 results on Mar 17, before the opening bell. Last quarter, the company???s loss was wider than expected.

                                    Use Rising P/E Strategy to Land Up on 5 Winning Stocks

                                    Cross the age-old barrier of low P/E investing, bet on these five stocks that boast rising P/E.

                                      Is BioDelivery Sciences (BDSI) a Great Growth Stock?

                                      BioDelivery Sciences (BDSI) is seeing solid earnings estimate revision activity, and is a great company from a Zacks Growth perspective.

                                        Is the Options Market Predicting a Spike in BioDelivery (BDSI) Stock?

                                        Options traders are pricing in a big move for BioDelivery (BDSI) shares as its huge implied volatility could mean there's a trade developing.

                                          Endo International (ENDP): Can the Stock Rebound in 2017?

                                          Can Endo make a comeback in 2017 seeing that the company is presently in the middle of the drug pricing controversy?

                                            Endo (ENDP) Inks Deal to Return Belbuca Rights to BioDelivery

                                            Endo (ENDP) announced that it has entered into an agreement to return the rights for Belbuca to BioDelivery (BDSI).

                                              Company News for November 10, 2016

                                              Companies in the News are: BDSI,DISH,EGRX,HCAP